Study of Bronchoscopic Lung Volume Reduction Using Thermoablation for Severe Emphysema in Adults Aged 40 to 75
Led by IHF GmbH - Institut für Herzinfarktforschung · Updated on 2025-08-24
224
Participants Needed
12
Research Sites
83 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating bronchoscopic lung volume reduction using thermoablation as a treatment for patients with severe emphysema. This prospective, two-arm, randomized, open-label trial compares this intervention combined with standard conservative therapy against standard therapy alone, following Global Initiative for Chronic Obstructive Lung Disease GOLD guidelines. The study aims to contribute evidence on the benefits and safety of this procedure to provide appropriate care for emphysema patients.
The trial involves two groups one receiving bronchoscopic lung volume reduction with thermal ablation using the InterVaporAE System in addition to standard care, and the other receiving only standard conservative therapy. The InterVaporAE System delivers heated water vapor to targeted lung areas, causing tissue remodeling and volume reduction. Participants in the intervention group may receive up to two partial treatments.
Participants will be monitored over several months with assessments including patient-reported quality of life, lung function tests like FEV1 and residual volume, vital status checks, 6-minute walk tests, and monitoring for serious adverse events and exacerbations. Follow-up evaluations occur at 3, 9, and 12 months, with the primary outcome measured at 9 months. The study duration and procedures are designed to evaluate the impact and safety of the bronchoscopic treatment compared to standard care.
CONDITIONS
Brief Title
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
Research Team
F
Felix Herth, MD
L
Leschek Brachmann, Masters of Science
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Severe bilateral heterogeneous emphysema of the upper lobes in GOLD stage 3 or 4
Evidence of severe emphysema on high-resolution CT scan within 6 months
Functional evidence of severe pulmonary hyperinflation
FEV1 post lysis between 20% and less than 45%
Total lung capacity at least 100%
Residual volume greater than 175%
Arterial blood gas values: PaCO2 at most 50 mmHg, PaO2 more than 50 mmHg on room air
Marked dyspnoea with score of 2 or more on the mMRC scale
Able to walk more than 140 meters in 6 minutes
Exhaustion of conservative treatment options
Optimized medical therapy per GOLD guidelines
Non-smoker for at least 6 months prior to inclusion
Completed pulmonary and geriatric rehabilitation within the last 4 years
Participation in regular physical activities beyond daily living
Mentally and physically able to participate in study procedures
Indication confirmed by interdisciplinary case conference
You will not qualify if you...
Conditions interfering with trial follow-up, bronchoscopy, or outcomes
DLCO less than 20%
Body mass index less than 18 or greater than 32 kg/m2
Pulmonary hypertension (peak systolic PAP over 45 mmHg or mean PAP over 25 mmHg)
Clinically significant bronchiectasis
Pneumothorax or pleural effusions within last 6 months
Previous lung or heart surgeries in target lobes
Recent respiratory infection or COPD exacerbation within 6 weeks
Unstable COPD including frequent hospitalizations or recent hospital stay
Daily use of systemic steroids over 5 mg prednisolone
Large bulla or paraseptal emphysema in target lobe
Coagulopathy or current anticoagulant use
Presence or recent removal of endobronchial valves or coils
Previous endobronchial polymer or adhesive treatment
Immune disorders requiring immunosuppressants
Recent myocardial infarction or acute coronary syndrome
Recent hospitalization for left heart failure
Clinically leading asthma or alpha-1-antitrypsin deficiency
Known sensitivity to bronchoscopy medications
Life expectancy less than 12 months
Recent use of morphine derivatives
Pregnancy at time of inclusion
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - Not specified
Participants receive bronchoscopic lung volume reduction using the InterVapor®-System device to ablate targeted lung regions, potentially in up to two partial interventions.
Up to 2 bronchoscopic intervention visits
Long-term Monitoring
Duration - Up to 12 months
Participants are monitored for changes in lung function, quality of life, and safety outcomes following treatment or standard care.
Visits at 3, 9, and 12 months post intervention or enrollment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Design of the multicentre randomised controlled BENTO trial to demonstrate patient-relevant benefit of bronchoscopic lung volume reduction using thermal vapour ablation in the German healthcare system for patients with upper lobe emphysema: a study protocol.